Intensified polarization in R&D investment among listed pharms
Although it is estimated there were more than 6 listed pharmaceutical companies investing more than KRW 100 billion into R&D in a year, there were also a number of pharmaceutical products spending less than 1% of their sales into R&D, which raised a criticism about polarization of R&D in the phar...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
